Discovery of novel Leishmania major trypanothione synthetase inhibitors by high-throughput screening.
Autor: | Phan TN; Host-Parasite Research Laboratory, Discovery Biology, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea., Park KP; Screening Discovery Platform, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea., Benítez D; Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay., Comini MA; Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay., Shum D; Screening Discovery Platform, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea., No JH; Host-Parasite Research Laboratory, Discovery Biology, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea. Electronic address: joohwan.no@ip-korea.org. |
---|---|
Jazyk: | angličtina |
Zdroj: | Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Dec 31; Vol. 637, pp. 308-313. Date of Electronic Publication: 2022 Nov 17. |
DOI: | 10.1016/j.bbrc.2022.11.044 |
Abstrakt: | Leishmaniasis is an infectious disease caused by obligate intracellular protozoa of the genus Leishmania with high infection and death rates in developing countries. New drugs with better pharmacological performance with regards to safety, efficacy, toxicity, and drug resistance than those/the ones currently used are urgently needed. Trypanothione synthetase (TryS) is an attractive target for the development of drugs against leishmaniasis because it is specific and essential to kinetoplastid parasites. In this study, Leishmaniamajor TryS was expressed and purified, and the kinetic parameters of purified TryS were determined. To identify novel inhibitors of LmTryS, a high-throughput screening (HTS) assay was developed and used to screen a library of 35,040 compounds. In the confirmatory assay, 42 compounds displayed half maximal inhibitory concentration (IC Competing Interests: Declaration of competing interest The authors declare no conflicts of interest. (Copyright © 2022. Published by Elsevier Inc.) |
Databáze: | MEDLINE |
Externí odkaz: |